Ratings by H.C. Wainwright (Matthew Caufield)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | FibroBiologics | FBLG | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2026 | Ardelyx, Inc | ARDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Kodiak Sciences Inc. | KOD | Maintain | Buy (Buy) |
|
Details | ||
| 1/22/2026 | Kodiak Sciences Inc. | KOD | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2026 | Zenas Biopharma | ZBIO | Maintain | Buy (Buy) |
|
Details | ||
| 1/2/2026 | FibroBiologics | FBLG | Maintain | Buy (Buy) |
|
Details | ||
| 12/16/2025 | Zenas Biopharma | ZBIO | Maintain | Buy (Buy) |
|
Details | ||
| 12/2/2025 | Akebia Therapeutics | AKBA | Maintain | Buy (Buy) |
|
Details | ||
| 11/17/2025 | Kodiak Sciences Inc. | KOD | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2025 | Kodiak Sciences Inc. | KOD | Upgrade | Buy (Neutral) |
18.49 (24.86) |
34.45% | Details | |
| 11/5/2025 | FibroBiologics | FBLG | Maintain | Buy (N/A) |
|
Details | ||
| 10/31/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Akebia Therapeutics | AKBA | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2025 | Zenas Biopharma | ZBIO | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (Buy) |
|
Details | ||
| 10/9/2025 | Zenas Biopharma | ZBIO | Maintain | Buy (Buy) |
|
Details | ||
| 10/1/2025 | Opus Genetics | IRD | Maintain | Buy (Buy) |
|
Details | ||
| 9/16/2025 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/12/2025 | FibroBiologics | FBLG | Maintain | Buy (Buy) |
|
Details | ||
| 9/8/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (Buy) |
|
Details | ||
| 8/22/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2025 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2025 | FibroBiologics | FBLG | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (N/A) |
|
Details | ||
| 7/28/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2025 | Opus Genetics | IRD | Maintain | Buy (Buy) |
|
Details | ||
| 6/18/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (Buy) |
|
Details | ||
| 6/18/2025 | Ardelyx, Inc | ARDX | New Coverage | Buy (N/A) |
3.55 (6.19) |
74.37% | Details | |
| 6/9/2025 | Lyra Therapeutics | LYRA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/9/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (Buy) |
|
Details | ||
| 6/4/2025 | Akebia Therapeutics | AKBA | New Coverage | Buy (N/A) |
3.42 (1.27) |
-62.87% | Details | |
| 5/2/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2025 | Opus Genetics | IRD | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2025 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/25/2025 | Opthea Ltd. | OPT | Downgrade | Neutral (Buy) |
3.41 (3.41) |
0% | Details | |
| 3/21/2025 | Optinose | OPTN | Downgrade | Neutral (Buy) |
9.15 (9.60) |
4.92% | Details | |
| 3/20/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Buy (Buy) |
|
Details | ||
| 3/7/2025 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (Buy) |
|
Details | ||
| 2/10/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (Buy) |
|
Details | ||
| 2/6/2025 | Eyenovia | EYEN | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/30/2025 | Surrozen Inc. | SRZN | New Coverage | Buy (N/A) |
11.25 (27.04) |
140.36% | Details | |
| 1/3/2025 | Optinose | OPTN | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2024 | Zenas Biopharma | ZBIO | New Coverage | Buy (N/A) |
8.92 (25.28) |
183.41% | Details | |
| 12/12/2024 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (Buy) |
|
Details | ||
| 11/18/2024 | Eyenovia | EYEN | Downgrade | Neutral (Buy) |
0.10 (15.82) |
15720% | Details | |
| 11/13/2024 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
1.14 (4.89) |
328.95% | Details | |
| 10/30/2024 | FibroBiologics | FBLG | New Coverage | Buy (N/A) |
2.75 (0.44) |
-84% | Details | |
| 9/19/2024 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (Buy) |
|
Details | ||
| 9/5/2024 | Kodiak Sciences Inc. | KOD | New Coverage | Neutral (N/A) |
2.42 (24.86) |
927.27% | Details | |
| 9/3/2024 | Opthea Ltd. | OPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2024 | Lyra Therapeutics | LYRA | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/14/2024 | Ocuphire | OCUP | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | Eyenovia | EYEN | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Buy (N/A) |
23.78 (11.67) |
-50.93% | Details | |
| 7/19/2024 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (Buy) |
|
Details | ||
| 7/10/2024 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
12.89 (26.59) |
106.28% | Details | |
| 7/9/2024 | HilleVax, Inc. | HLVX | Downgrade | Neutral (Buy) |
1.64 (2.09) |
27.44% | Details | |
| 5/7/2024 | Lyra Therapeutics | LYRA | Downgrade | Neutral (Buy) |
0.52 (1.28) |
146.15% | Details | |
| 3/11/2024 | Optinose | OPTN | New Coverage | Buy (N/A) |
1.68 (9.60) |
471.43% | Details | |
| 12/13/2023 | HilleVax, Inc. | HLVX | New Coverage | Buy (N/A) |
13.95 (2.09) |
-85.02% | Details | |
| 8/31/2023 | Lyra Therapeutics | LYRA | New Coverage | Buy (N/A) |
3.36 (1.28) |
-61.9% | Details | |
| 8/9/2023 | Phathom Pharmaceuticals | PHAT | New Coverage | Buy (N/A) |
14.72 (10.67) |
-27.51% | Details | |
| 5/2/2023 | Iveric Bio | ISEE | Downgrade | Neutral (Buy) |
38.05 (39.95) |
4.99% | Details | |
| 11/18/2022 | 4D Molecular Therapeutics | FDMT | New Coverage | Buy (N/A) |
22.40 (8.48) |
-62.14% | Details | |
| 10/5/2022 | Eyenovia | EYEN | New Coverage | Buy (N/A) |
2.15 (15.82) |
635.81% | Details | |
| 7/18/2022 | Oyster Point Pharma | OYST | New Coverage | Buy (N/A) |
4.43 (11.17) |
152.14% | Details | |
| 3/11/2022 | Gemini Therapeutics Inc. | GMTX | Downgrade | Neutral (Buy) |
1.49 (1.35) |
-9.4% | Details | |
| 3/1/2022 | Gemini Therapeutics Inc. | GMTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2021 | Ocuphire | OCUP | New Coverage | Buy (N/A) |
3.48 (1.17) |
-66.38% | Details |
